NEW YORK – KeyGene said today that it has extended a worldwide, non-exclusive license agreement that grants Guardant Health the right to implement certain, undisclosed, next-generation sequencing technologies for which KeyGene holds patents.
The statement comes after another announcement on April 7 that the firm had also extended an existing worldwide non-exclusive license granted to LGC Biosearch Technologies for the commercial offering and use of KeyGene's patented SBG (Sequence-Based Genotyping) technology across agricultural and life sciences applications.